Oct 29, 2026 earnings call — Expanded HD dialyzer rollout and updated 2026 guidance
Company narrowed full-year adjusted operating income guidance to $2.175 billion to $2.25 billion.
Revenue $3.6B (est $3.5B) · EPS $3.82 (est $3.57)
Key quotes
"As a result, we will begin our national rollout next week and expect a swift network-wide transition, bringing expanded HD to the vast majority of eligible patients in November."
"We now expect IKC to deliver at least $65 million of adjusted operating income in 2026, an increase of at least $25 million over the prior guidance."
"Going forward, we expect that growth in technology investments will decelerate."
Analyst Q&A 6
ESRD rule impact and IKC growth
Q (Albert Rice · UBS): Analyst asked how the finalized ESRD rule changes affect reimbursement, especially for phosphate binders, and whether the adjustments match the company's expectations. He also asked if IKC is now consistently profitable and whether the company will grow that business.
A: Management said their current estimate is the net impact for full year '27 will be 1.5% to 2%, noting the rule now treats TDAPA add-ons differently and the TDAPA component was large in Q1 but should fall later. They also said IKC is now at a point of consistent profitability and they want to pursue more business, but only with healthy contracts and aligned physician partners.
"I'll start with the big picture, which is our estimate right now, and I'll emphasize that it's an estimate, is that the net impact for us for the full year '27 will be 1.5% to 2%." — Joel Ackerman (CFO)
Q4 treatments, ACA headwind, HHS plan
Q (Andrew Mok · Barclays): Analyst asked if leaving full year treatment guide unchanged implies treatments per normalized day rise more than 1% in Q4 and whether that is reasonable given higher missed treatments. He also asked for an update on the ACA exchange headwind and impressions of the HHS Kidney Care Plan.
A: Management said the analyst's math is about right: Q4 uptick should come from missed treatment rates reverting to a normal year-over-year pattern and from stronger census growth in Q3. They said commercial mix is down a bit as expected and they remain on track for a $40 million year-over-year headwind for '26. On the HHS plan, management said they broadly support its goals and want to be at the table, but they were frustrated by how dialysis was portrayed and said the economic ecosystem and government payment dynamics need more work.
"What we saw in Q3 was missed treatment rates about 20 basis points higher than expected and higher than last year." — Joel Ackerman (CFO)
Modeling 2027 and new dialyzer effects
Q (Pito Chickering · Deutsche Bank): Analyst asked for the known puts and takes for 2027 including volume growth, revenue per treatment, IT spend, pharmaceutical costs, and any IKC tailwinds. He also asked whether the new HD dialyzer has reduced missed treatments and if it will shift patients back from home hemo.
A: Management said it's early for full 2027 guidance but they expect volume growth in 2027 to be higher than in 2026. They expect an RPT headwind from commercial mix (ACA) and a cost tailwind from lower pharmaceutical costs, especially binders, while IT spend will decelerate but not fall. On the dialyzer, they said it's too soon to tell effects on missed treatments and they doubt it will drive large shifts in modality choice.
"On the volume side, I would say we expect volume growth in 2027 to be higher than volume growth in 2026." — Joel Ackerman (CFO)
Fresenius site closures and AKF/CPA details
Q (Kevin Fischbeck · BofA): Analyst asked whether volume gains from Fresenius site closures showed up in Q3 versus Q2 and asked how improved mortality from the new dialyzer should affect profitability and payer mix. He also asked for a reminder on the company's exposure to AKF charitable premium assistance.
A: Management said the impact from Fresenius site closures largely played out in Q1, so there was no change from Q2 to Q3. They said early dialyzer results suggest younger patients are benefiting too, so it is not simply adding Medicare treatments, but it's too early to know the final mix. On AKF/CPA, they said the program has long enabled patients to keep health coverage, most grants support government and supplemental coverage, the program has been scrutinized and found to benefit a vulnerable population, and reducing it would likely increase government-paid patients and reduce capital attraction.
"So it's basically a system that's been in place for many decades that enables patients, many who can no longer work full time due to kidney failure to maintain continuity of health coverage." — Javier Rodriguez (CEO)
Clinic utilization and depreciation
Q (Ryan Langston · TD Cowen): Analyst asked if raising clinic capacity utilization should become a higher priority and what actions could lift utilization. He also asked whether the current depreciation expense run rate will continue or fall further in Q4.
A: Management said they want higher capacity utilization and the best way to achieve it is by growing census; census is up a little more than 1% year-over-year and they have no plans to close clinics. On depreciation, they said it has declined for many years and they don't expect much more continued decline, so current levels are a reasonable spot.
"And that, we are doing that, as I mentioned before, our census count is up about 1%, a little bit more than 1% year-over-year, and we plan on continuing that." — Joel Ackerman (CFO)
ESRD TDAPA details: binders and DefenCath
Q (William Westerfield · Wolfe): Analyst asked how the 3.1% TDAPA increase breaks down between the binder $12-plus number versus current binder revenue per treatment for Medicare patients, and how DefenCath reimbursement will develop across 2027.
A: Management said binders are largely in line with their expectations and they do not think binders drive much of the 3.1% change. They said the bigger factor is DefenCath, and because the add-on is post-TDAPA it will be recalculated every quarter; they expect that TDAPA amount to drop significantly from Q1 to Q2 and to stay low or decline further through the back half of 2027. They also said they have limited visibility into industry utilization trends for the rest of 2026.
"And the important thing to realize on that is because it's a post-TDAPA add-on payment, it will get recalculated every quarter based on updated volume and updated ASP." — Joel Ackerman (CFO)